Last updated: February 22, 2026
What is the drug associated with NDC 42023-0110?
NDC 42023-0110 refers to Ertapenem for injection (brand name: Invanz). It is an injectable carbapenem antibiotic approved for complicated intra-abdominal infections, pelvic infections, diabetic foot infections, and community-acquired pneumonia.
What are the current market conditions?
Market Size and Demand
- Global antibiotic market: Estimated at $48.2 billion in 2022 with a compound annual growth rate (CAGR) of 3.8% (Grand View Research).
- Injectable antibiotics segment: Constitutes approximately 25-30% of the total antibiotic market.
- Ertapenem sales: In 2022, U.S. sales exceeded $480 million, driven by hospital and outpatient settings (IQVIA).
Market Drivers
- Growing prevalence of hospital-acquired infections.
- Rising incidences of multidrug-resistant organisms.
- Increased adoption of broad-spectrum antibiotics for serious infections.
- Expanding outpatient infusion treatments.
Competitive Landscape
- Main competitors include meropenem, imipenem, and ertapenem formulations from Pfizer, Merck, and other generic manufacturers.
- Patent status: Pfizer’s Invanz lost patent exclusivity in 2017, leading to increased generic competition.
- Price sensitivity increases as generics dominate.
What are the regulatory considerations?
- FDA approval status: Approved for multiple indications since 2001.
- Patent expirations: Patents for branded formulations expired, enabling generic manufacturing.
- Pricing policies: Hospital and insurance negotiations heavily influence net prices.
What are the current price trends?
Brand vs. Generic Prices
| Formulation |
Estimated Wholesale Acquisition Cost (WAC) per 1g dose |
Notes |
| Invanz (Brand) |
$80 - $100 |
Higher in hospitals, variable with contracts. |
| Generic ertapenem |
$50 - $70 |
Significantly lower, increasing uptake. |
Factors Influencing Price
- Supply chain disruptions: Shortages can temporarily inflate prices.
- Market entry of generics: Pushes down prices, sometimes by 20-40% within 12 months.
- Reimbursement policies: CMS and private insurers favor cost-effective generics.
What are the projections for pricing over the next five years?
Price Trend Forecast
| Year |
Estimated WAC per 1g dose |
Change from prior year |
Comments |
| 2023 |
$65 - $90 |
-2% to +3% |
Slight decline expected due to generic competition. |
| 2024 |
$60 - $85 |
-3% to +2% |
Continued downward pressure as generics dominate. |
| 2025 |
$55 - $80 |
-4% to +3% |
Market saturation and cost containment policies take effect. |
| 2026 |
$50 - $75 |
-5% to +3% |
Prices stabilize at lower levels; hospital contracts influence pricing. |
| 2027 |
$50 - $70 |
Stable or slight decline |
Generic availability constrains escalation. |
Market volume adjustments
- Demand will stabilize with steady use in hospital settings.
- Outpatient use expected to grow marginally due to expanded outpatient infusion services.
- Price reductions are likely to be offset by increased volume.
Key Market Dynamics
- Generic proliferation: Expected to further decrease prices.
- Healthcare policies: Push toward cost-effective therapies may limit brand prescribing.
- Infection trend: Persistent rise in resistant infections sustains demand for carbapenems.
Key Takeaways:
- The market for erdapenem (NDC 42023-0110) faces significant downward price pressure due to patent expiry and generic competition.
- Wholesale acquisition costs are projected to decline 15-20% over five years, stabilized around $50-$70 per 1g dose.
- Demand remains steady in hospital and outpatient settings, partially offsetting price declines.
- Market growth will depend on infection rates and the emergence of resistant organisms.
- Pricing strategies will depend on payer negotiations, market share, and regulatory factors.
FAQs
1. How does generic entry impact the pricing of erdapenem?
Generic entry typically reduces prices by 20-40% within a year, with further declines as market competition intensifies.
2. What factors could influence demand for erdapenem?
Increases in multidrug-resistant infections, hospital infection rates, and expansion of outpatient infusion services.
3. Are there upcoming regulatory approvals that could affect market dynamics?
No significant new indications or approvals for erdapenem are anticipated in the immediate future.
4. How do hospital formularies influence the market?
Hospitals prioritize cost-effective drugs; favoring generics reduces brand utilization and influences overall pricing.
5. What are the key opportunities for manufacturers?
Focus on cost containment, expanding outpatient use, and differentiating formulations with combination therapies or extended indications.
References
[1] Grand View Research. Antibiotics Market Size & Share Report, 2022.
[2] IQVIA. U.S. Pharmaceutical Market Data, 2022.
[3] FDA. Invanz (Ertapenem) Approval History.
[4] Pfizer. Invanz Product Information.
[5] Patents and Exclusivity Information. Drugs.com, 2022.
